|Mr. Amit D. Munshi||Pres, CEO & Director||1.11M||N/A||1968|
|Mr. Kevin R. Lind||Exec. VP & CFO||648.57k||N/A||1976|
|Mr. Steven W. Spector||Exec. VP, Gen. Counsel & Sec.||700.15k||1.02M||1965|
|Mr. Vincent E. Aurentz||Exec. VP & Chief Bus. Officer||751.46k||N/A||1968|
|Dr. Preston S. Klassen||Exec. VP and Head of R&D||667.37k||N/A||1969|
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 6.